Biotechnology | Disease | FDA | Oncology | Therapeutics
Genentech drug Tarceva (erlotinib) was approved
On Nov. 18, 2004, the U.S. Food and Drug Administration (FDA) announced it had approved Genentech’s drug Tarceva…
-
-
Touro University was founded
In 2004, Touro University Nevada (TUN), located in Henderson, was founded as a private, non-profit institution of higher…
-
The Scripps Research Institute announced the establishment of a major science center in Palm Beach County, Florida
On Oct. 9, 2003, The Scripps Research Institute (TSRI) announced the establishment of a major science center in…
-
Biotechnology | HIV | Infectious Disease | NIH | Vaccine
$81 million was awarded by NIAID through four new contracts to support development of candidate HIV vaccines
On Sept. 29, 2003, $81 million was awarded by National Institute of Allergy and Infectious Diseases (NIAID) through…
-
FDA approved an expanded indication for ENBREL (etanercept) to inhibit progression of structural damage of active arthritis
On Aug. 25, 2003, the FDA approved an expanded indication for ENBREL (etanercept) to inhibit the progression of…
-
Biotechnology | Disease | FDA | Medicine | Therapeutics
Long-term efficacy and safety of etanercept was found in children with polyarticular-course juvenile rheumatoid arthritis
On Jan. 10, 2003, long-term efficacy and safety of etanercept (Enbrel) was found in children with polyarticular-course juvenile…
-
The Institute for Collaborative Biotechnologies was founded
In 2003, The Institute for Collaborative Biotechnologies (ICB) was founded as an Army-sponsored University Affiliated Research Center (UARC)….
-
Biotechnology | Disease | FDA
Genentech drug Pegasys (peginterferon alfa-2a) approved
On Dec. 3, 2002, Genentech drug Pegasys (peginterferon alfa-2a) was approved by the Food and Drug Administration (FDA)…
-
Medicine | NIH | U.S. Congress
Richard H. Carmona was sworn in as U.S. Surgeon General
On Aug. 5, 2002, President George W. Bush appointed Richard H. Carmona as U.S. Surgeon General, one of…
-
Stanford researchers became the first to use gene expression profiling to predict cancer outcomes
In 2002, Stanford researchers became the first to use gene expression profiling to predict cancer outcomes. The research…
-
The Nevada Cancer Institute was founded
In 2002, the Nevada Cancer Institute (NVCI), founded in 2002 and located in Summerlin, was a non-profit organization…
-
Biotechnology | FDA | Medicine | Therapeutics
The acquisition of Immunex by Amgen for $16 billion was announced
On Dec. 17, 2001, the acquisition of Immunex by Amgen was announced for $16 billion in stock and…
-
Stanford researchers identified a novel gene family involved in asthma
On Nov. 19, 2001, researchers at Lucile Packard Children’s Hospital at Stanford announced they had identified a novel…
-
Livermore National Lab announced partnership with BioLuminate to develop ‘Smart Probe’ for breast cancer detection
On Jan. 10, 2001, Livermore National Laboratory announced a partnership with BioLuminate to develop ‘Smart Probe’ tool for…
-
Moores Cancer Center at UC San Diego achieved NCI designated comprehensive cancer center status
In 1978, Moores Cancer Center (MCC) at UC San Diego achieved National Cancer Institute (NCI) designated comprehensive cancer…
-
Compulsive shopping research at Stanford seeks to treat mysterious disorder
On Dec. 16, 2002, researchers at Stanford University Medical Center announced they were continuing a multi-year clinical trial…
-
Genentech drug TNKase (tenecteplase) was approved
On June 2, 2000, the U.S. Food and Drug Administration announced it had approved Genentech’s drug TNKaseﾮ (tenecteplase)….
-
QB 3 was founded as the University of California’s hub for innovation and entrepreneurship in life science
In 2000, QB3 founded as the University of California’s hub for innovation and entrepreneurship in life science, with…
-
Stanford researchers first used gene expression profiling to distinguish cancer sub-types
In 2000, Stanford researchers led by Ash Alizadeh announced they had used gene expression profiling to identify two…
-
The University of California, Riverside Center for Nanoscale Science and Engineering was established
In 2000, the University of California, Riverside Center for Nanoscale Science and Engineering was established to capitalize on…
-
The Norris Foundation committed $15 million toward construction of the Harlyne J Norris Research Tower
On Jan. 10, 2012, the Norris Foundation made a $15 million commitment toward construction of the Harlyne J….
-
The Stanford Hospital Center for Clinical Sciences Research building opened
In 2000, the Center for Clinical Sciences Research building opened, and is an example of a fully integrated…
-
The Buck Institute for Research on Aging opened its doors
On Sept. 30, 1999, the Buck Institute for Research on Aging, named for Marin County philanthropists Leonard and…
-
Gilead Sciences and NeXstar Pharmaceuticals announced completion of their merger
On Jul. 29, 1999, Gilead Sciences and NeXstar Pharmaceuticals announced the closing of their agreement whereby Gilead acquired…
-
Biotechnology | Diagnostics | NIH | Oncology | Therapeutics
UCSF Cancer Research Institute received NCI Comprehensive Cancer Center designation
In 1999, University of California at San Francisco Cancer Research Institute received NCI Comprehensive Cancer Center designation. The…
-
Biotechnology | Diagnostics | Genomics | NIH | Therapeutics
Livermore National Lab work was completed on the mouse genome as part of Laboratory efforts in comparative genomics
On Oct. 30, 1999, Livermore National Lab work completed work on the mouse genome as part of Laboratory…
-
The Del E. Webb Center for Neuroscience and Aging was established at The Burnham Institute
In 1999, the Del E. Webb Center for Neuroscience and Aging, which focuses on diseases such as stroke,…
-
Biotechnology | Diagnostics | Disease | FDA | Oncology | Therapeutics | Women's Health
The FDA approved the monoclonal antibody Herceptin (Trastuzumab) for treatment of metastatic breast cancer
On Sept. 25, 1998, the U.S. Food and Drug Administration (FDA) approved the monoclonal antibody Herceptin (Trastuzumab) for…
-
Biotechnology | Diagnostics | NIH | Non-Profit Research | Oncology | Therapeutics | U.S. Congress | Women's Health
The Stamp Out Breast Cancer stamp was first issued
On Jul. 29, 1998, the Stamp Out Breast Cancer stamp was first issued. The driving force behind the…
-
Biotechnology | FDA | Oncology | Therapeutics
The FDA approved Genentech drug Xeloda (capecitabine)
On April 30, 1998, the U.S. Food and Drug Administration (FDA) approved the Genentech’s drug Xeloda (capecitabine) for…
